Log in

BioScrip Stock Price, News & Analysis (NASDAQ:BIOS)

$3.64
+0.06 (+1.68 %)
(As of 10/20/2019 03:09 PM ET)
Today's Range
$3.53
Now: $3.64
$3.64
50-Day Range
$2.98
MA: $3.42
$3.79
52-Week Range
$1.56
Now: $3.64
$4.14
Volume540,039 shs
Average Volume930,969 shs
Market Capitalization$470.22 million
P/E RatioN/A
Dividend YieldN/A
Beta0.45
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. Read More…

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$708.90 million
Book Value($1.12) per share

Profitability

Net Income$-51,690,000.00

Miscellaneous

Employees2,043
Market Cap$470.22 million
Next Earnings Date11/6/2019 (Confirmed)
OptionableOptionable

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.


BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) released its quarterly earnings results on Tuesday, July, 30th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The firm had revenue of $191.52 million for the quarter, compared to the consensus estimate of $185.73 million. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for BioScrip.

How can I listen to BioScrip's earnings call?

BioScrip will be holding an earnings conference call on Wednesday, November 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for BIOS?

5 equities research analysts have issued 12 month target prices for BioScrip's stock. Their forecasts range from $2.51 to $10.00. On average, they anticipate BioScrip's share price to reach $4.95 in the next year. This suggests a possible upside of 36.0% from the stock's current price. View Analyst Price Targets for BioScrip.

What is the consensus analysts' recommendation for BioScrip?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.

What are Wall Street analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:
  • 1. According to Zacks Investment Research, "BioScrip exited the first quarter of 2019 with loss narrower than the consensus estimate and revenues ahead of the mark. BioScrip’s consistent growth in the Infusion services business and the diverse measures adopted by management to drive growth bolsters our confidence in the stock. We are optimistic about the company’s impending merger with Option Care and particularly, its fortified liquidity and flexibility that can be achieved via an optimized capital structure after the merger. In the last six months, BioScrip has consistently underperformed the industry it belongs to. BioScrip currently anticipates the merger with Option Care to close in the second half of 2019." (6/20/2019)
  • 2. Barrington Research analysts commented, "We think they should have held one given that management is currently engaged in selling BIOS investors on the benefits of the pending Option Care transaction." (5/3/2019)

Has BioScrip been receiving favorable news coverage?

Media coverage about BIOS stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioScrip earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for BioScrip.

Are investors shorting BioScrip?

BioScrip saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 9,810,000 shares, an increase of 19.2% from the August 30th total of 8,230,000 shares. Based on an average daily volume of 1,150,000 shares, the short-interest ratio is presently 8.5 days. Currently, 7.5% of the shares of the company are sold short. View BioScrip's Current Options Chain.

Who are some of BioScrip's key competitors?

What other stocks do shareholders of BioScrip own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioScrip investors own include Abraxas Petroleum (AXAS), Trevena (TRVN), Northern Oil & Gas (NOG), Acasti Pharma (ACST), Advanced Micro Devices (AMD), General Electric (GE), JPMorgan Chase & Co. (JPM), Opko Health (OPK), Seanergy Maritime (SHIP) and Rite Aid (RAD).

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 52)
  • Mr. John McMahon, VP, Controller & Chief Accounting Officer (Age 54)
  • Mr. Vito Ponzio Jr., Chief Admin. Officer & Sr. VP (Age 64)

Who are BioScrip's major shareholders?

BioScrip's stock is owned by a variety of of retail and institutional investors. Top institutional investors include North Star Investment Management Corp. (0.02%). Company insiders that own BioScrip stock include Daniel E Greenleaf and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

Which major investors are buying BioScrip stock?

BIOS stock was purchased by a variety of institutional investors in the last quarter, including North Star Investment Management Corp.. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf and Stephen Deitsch. View Insider Buying and Selling for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $3.64.

How big of a company is BioScrip?

BioScrip has a market capitalization of $470.22 million and generates $708.90 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. BioScrip employs 2,043 workers across the globe.View Additional Information About BioScrip.

What is BioScrip's official website?

The official website for BioScrip is http://www.bioscrip.com/.

How can I contact BioScrip?

BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (NASDAQ BIOS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  305 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  555
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2019 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel